FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111699498> ?p ?o ?g. }

• W2111699498 endingPage "1838" @default.
• W2111699498 startingPage "1831" @default.
• W2111699498 abstract "Purpose To report the anatomic and functional outcomes of intravitreal clindamycin and dexamethasone for the treatment of zone 1 toxoplasmic retinochoroiditis (TRC). Patients had 1 or more of the following indications for local therapy: intolerance to oral medication, contraindication to oral medication because of pregnancy, lack of response despite oral antimicrobial treatment, or treatment with concomitant oral and local therapy to avoid or limit foveal or optic disc involvement. Design Noncomparative, retrospective, multicentric interventional case series. Participants We reviewed the medical records of 12 consecutive patients (eyes) with posterior pole (zone 1) TRC who were treated weekly or every 4 weeks (during pregnancy) with intravitreal injections of clindamycin (1.5 mg/0.1 ml) and dexamethasone (400 μg/0.1 ml). Methods Ophthalmic evaluation included Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA); assessment of central macular thickness (CMT); resolution of inflammation by optical coherence tomography (OCT), clinical examination, and fluorescein angiography; and assessment of adverse events. Patients were followed for 24 months. Main Outcome Measures Resolution of TRC, changes in BCVA, and OCT. Results Resolution of TRC was achieved in all cases with a mean number of injections of 3.6 (range: 2–5 injections) with a mean interval of 15.5±4 days. At 24 months a significant reduction in CMT by OCT was observed, from 387.6±70.1 μm to 185.2±44.7 μm (P = 0.0004). Baseline BCVA was logarithm of the minimal angle of resolution (logMAR) 1±0.4 (20/200), which improved to 0.5±0.4 (20/63) (P = 0.002) at the end of follow-up. Ten eyes (83.3%) improved ≥2 ETDRS lines of BCVA, and 2 eyes (20%) remained stable at 24 months. One patient's vision was limited because of macular scarring. No ocular or systemic adverse events were observed. No recurrences at 24 months of follow-up were observed. Conclusions The combination of intravitreal clindamycin and dexamethasone was associated with resolution of zone 1 TRC and functional and anatomic improvement in patients who did not tolerate, had contraindications to, or did not respond to oral medications. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. To report the anatomic and functional outcomes of intravitreal clindamycin and dexamethasone for the treatment of zone 1 toxoplasmic retinochoroiditis (TRC). Patients had 1 or more of the following indications for local therapy: intolerance to oral medication, contraindication to oral medication because of pregnancy, lack of response despite oral antimicrobial treatment, or treatment with concomitant oral and local therapy to avoid or limit foveal or optic disc involvement. Noncomparative, retrospective, multicentric interventional case series. We reviewed the medical records of 12 consecutive patients (eyes) with posterior pole (zone 1) TRC who were treated weekly or every 4 weeks (during pregnancy) with intravitreal injections of clindamycin (1.5 mg/0.1 ml) and dexamethasone (400 μg/0.1 ml). Ophthalmic evaluation included Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA); assessment of central macular thickness (CMT); resolution of inflammation by optical coherence tomography (OCT), clinical examination, and fluorescein angiography; and assessment of adverse events. Patients were followed for 24 months. Resolution of TRC, changes in BCVA, and OCT. Resolution of TRC was achieved in all cases with a mean number of injections of 3.6 (range: 2–5 injections) with a mean interval of 15.5±4 days. At 24 months a significant reduction in CMT by OCT was observed, from 387.6±70.1 μm to 185.2±44.7 μm (P = 0.0004). Baseline BCVA was logarithm of the minimal angle of resolution (logMAR) 1±0.4 (20/200), which improved to 0.5±0.4 (20/63) (P = 0.002) at the end of follow-up. Ten eyes (83.3%) improved ≥2 ETDRS lines of BCVA, and 2 eyes (20%) remained stable at 24 months. One patient's vision was limited because of macular scarring. No ocular or systemic adverse events were observed. No recurrences at 24 months of follow-up were observed. The combination of intravitreal clindamycin and dexamethasone was associated with resolution of zone 1 TRC and functional and anatomic improvement in patients who did not tolerate, had contraindications to, or did not respond to oral medications." @default.
• W2111699498 created "2016-06-24" @default.
• W2111699498 creator A5008720591 @default.
• W2111699498 creator A5021280194 @default.
• W2111699498 creator A5066959890 @default.
• W2111699498 creator A5076181472 @default.
• W2111699498 creator A5083646035 @default.
• W2111699498 date "2010-09-01" @default.
• W2111699498 modified "2023-10-01" @default.
• W2111699498 title "Intravitreal Clindamycin and Dexamethasone for Zone 1 Toxoplasmic Retinochoroiditis at Twenty-four Months" @default.
• W2111699498 cites W115239212 @default.
• W2111699498 cites W1675657014 @default.
• W2111699498 cites W1935941048 @default.
• W2111699498 cites W1966735715 @default.
• W2111699498 cites W1969003938 @default.
• W2111699498 cites W1974881857 @default.
• W2111699498 cites W1988283269 @default.
• W2111699498 cites W2008535411 @default.
• W2111699498 cites W2018343613 @default.
• W2111699498 cites W2025136878 @default.
• W2111699498 cites W2027400073 @default.
• W2111699498 cites W2033103553 @default.
• W2111699498 cites W2062865161 @default.
• W2111699498 cites W2068253039 @default.
• W2111699498 cites W2071273491 @default.
• W2111699498 cites W2098922030 @default.
• W2111699498 cites W2102505840 @default.
• W2111699498 cites W2106114797 @default.
• W2111699498 cites W2116826131 @default.
• W2111699498 cites W2118208608 @default.
• W2111699498 cites W2253810417 @default.
• W2111699498 cites W2462723562 @default.
• W2111699498 cites W4255030232 @default.
• W2111699498 doi "https://doi.org/10.1016/j.ophtha.2010.01.028" @default.
• W2111699498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20471684" @default.
• W2111699498 hasPublicationYear "2010" @default.
• W2111699498 type Work @default.
• W2111699498 sameAs 2111699498 @default.
• W2111699498 citedByCount "58" @default.
• W2111699498 countsByYear W21116994982012 @default.
• W2111699498 countsByYear W21116994982013 @default.
• W2111699498 countsByYear W21116994982014 @default.
• W2111699498 countsByYear W21116994982015 @default.
• W2111699498 countsByYear W21116994982016 @default.
• W2111699498 countsByYear W21116994982017 @default.
• W2111699498 countsByYear W21116994982018 @default.
• W2111699498 countsByYear W21116994982019 @default.
• W2111699498 countsByYear W21116994982020 @default.
• W2111699498 countsByYear W21116994982021 @default.
• W2111699498 countsByYear W21116994982022 @default.
• W2111699498 countsByYear W21116994982023 @default.
• W2111699498 crossrefType "journal-article" @default.
• W2111699498 hasAuthorship W2111699498A5008720591 @default.
• W2111699498 hasAuthorship W2111699498A5021280194 @default.
• W2111699498 hasAuthorship W2111699498A5066959890 @default.
• W2111699498 hasAuthorship W2111699498A5076181472 @default.
• W2111699498 hasAuthorship W2111699498A5083646035 @default.
• W2111699498 hasConcept C118487528 @default.
• W2111699498 hasConcept C126322002 @default.
• W2111699498 hasConcept C141071460 @default.
• W2111699498 hasConcept C167135981 @default.
• W2111699498 hasConcept C2777458120 @default.
• W2111699498 hasConcept C2778257484 @default.
• W2111699498 hasConcept C2779384505 @default.
• W2111699498 hasConcept C2780248432 @default.
• W2111699498 hasConcept C2780401358 @default.
• W2111699498 hasConcept C501593827 @default.
• W2111699498 hasConcept C71924100 @default.
• W2111699498 hasConcept C86803240 @default.
• W2111699498 hasConcept C89423630 @default.
• W2111699498 hasConceptScore W2111699498C118487528 @default.
• W2111699498 hasConceptScore W2111699498C126322002 @default.
• W2111699498 hasConceptScore W2111699498C141071460 @default.
• W2111699498 hasConceptScore W2111699498C167135981 @default.
• W2111699498 hasConceptScore W2111699498C2777458120 @default.
• W2111699498 hasConceptScore W2111699498C2778257484 @default.
• W2111699498 hasConceptScore W2111699498C2779384505 @default.
• W2111699498 hasConceptScore W2111699498C2780248432 @default.
• W2111699498 hasConceptScore W2111699498C2780401358 @default.
• W2111699498 hasConceptScore W2111699498C501593827 @default.
• W2111699498 hasConceptScore W2111699498C71924100 @default.
• W2111699498 hasConceptScore W2111699498C86803240 @default.
• W2111699498 hasConceptScore W2111699498C89423630 @default.
• W2111699498 hasIssue "9" @default.
• W2111699498 hasLocation W21116994981 @default.
• W2111699498 hasLocation W21116994982 @default.
• W2111699498 hasOpenAccess W2111699498 @default.
• W2111699498 hasPrimaryLocation W21116994981 @default.
• W2111699498 hasRelatedWork W1987334421 @default.
• W2111699498 hasRelatedWork W2072671252 @default.
• W2111699498 hasRelatedWork W2079523484 @default.
• W2111699498 hasRelatedWork W2082606620 @default.
• W2111699498 hasRelatedWork W2125418032 @default.
• W2111699498 hasRelatedWork W2295935431 @default.
• W2111699498 hasRelatedWork W2464605730 @default.
• W2111699498 hasRelatedWork W3015481187 @default.
• W2111699498 hasRelatedWork W3109463204 @default.
• W2111699498 hasRelatedWork W59883236 @default.

• next